tbuckley/cabot-search huggingface dataset:
Anticoagulation in cirrhosis: a new paradigm?
Authors: Filippo Leonardi, Nicola De Maria, Erica Villa
Journal: Clinical and Molecular Hepatology (2017)

The liver plays a crucial role in coagulation cascade. Global hemostatic process is profoundly influenced by the presence of liver disease and its complications. Patients with cirrhosis have impaired synthesis of most of the factors involved in coagulation and fibrinolysis process due to a reduced liver function and altered platelet count secondary to portal hypertension. Altered routine tests and thrombocytopenia were considered in the past as associated with increased risk of bleeding. These concepts explain both the routine use of plasma and/or platelets transfusion in patients with liver cirrhosis, especially before invasive procedures, and why these patients were considered "auto-anticoagulated". New recent evidences show that patients with liver cirrhosis have a more complex hemostatic alteration. Despite the presence of altered levels of factors involved in primary hemostasis, coagulation and fibrinolysis, patients with stable cirrhosis have a rebalanced hemostatic, which however can easily be altered by decompensation or infection, both in hemorrhagic or thrombotic direction. Patients with cirrhosis have an increased risk of venous thrombotic events (namely portal vein thrombosis) while bleeding seems to be related to the grade of portal hypertension rather than to a hemostatic imbalance. The use of anticoagulants both as treatment or prophylaxis is safe, reduces the rate of portal vein thrombosis and decompensation, and improves survival. Standard laboratory coagulation tests are unable to predict bleeding and are inadequate for the assessment of hemostatic status in these patients, hence more comprehensive tests are required to guide the management of thrombotic and bleeding complications.
Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebo-controlled trial
Authors: K. L. Margolis
Journal: JAMA (1990)

Concern about side effects constitutes a major deterrent to patient compliance with influenza vaccination, yet there is a paucity of data about the occurrence of adverse reactions in the population targeted for immunization. We conducted a randomized, double-blind, crossover trial to compare the frequency of adverse reactions following administration of 1988-1989 trivalent split-antigen influenza vaccine and saline placebo. Outpatient veterans 65 years of age or over (n = 336) were recruited by mail and were randomly assigned to receive vaccine followed 2 weeks later by placebo injection or placebo followed 2 weeks later by vaccine. There was no significant difference between influenza vaccine and placebo with respect to the proportion of subjects reporting disability or systemic symptoms.  ( JAMA . 1990;264:1139-1141)
First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.
Authors: D. Ross Camidge, Lyudmila Bazhenova, Ravi Salgia, Glen J. Weiss, Corey J. Langer, Alice Tsang Shaw, Narayana I. Narasimhan, David J. Dorer, Victor M. Rivera, Joshua Zhang, Tim Clackson, Frank G. Haluska, Scott N. Gettinger
Journal: Journal of Clinical Oncology (2013)

8031 Background: AP26113 is a novel tyrosine kinase inhibitor (TKI) that potently inhibits mutant activated forms of anaplastic lymphoma kinase (ALK+) and epidermal growth factor receptor (EGFRm), and TKI-resistant forms including L1196M (ALK) and T790M (EGFR). AP26113 does not inhibit native EGFR. Methods: The dose finding phase (3+3 design) of this phase I/II open-label, multicenter study is ongoing in pts with advanced malignancies (except leukemia) refractory to available therapies or for whom no standard treatment exists. Initial dosing is orally once daily. Results: As of 14 Jan 2013, 44 pts were enrolled: 30 mg n=3, 60 mg n=3, 90 mg n=8, 120 mg n=8, 180 mg n=11, 240 mg n=9, 300 mg n=2; 64% female, median age 60 yrs; diagnoses: non-small cell lung cancer (NSCLC, n=37), other (n=7). 26 pts discontinued: 18 disease progression, 6 adverse event (AE), 2 deaths (sudden death, hypoxia; both possibly related). Most common AEs: nausea (45%), fatigue (39%), diarrhea (27%); most common grade 3/4 treatment-related AE: diarrhea (5%). 2 dose limiting toxicities observed: grade 3 ALT increase, 240 mg; grade 4 dyspnea, 300 mg. Doses &lt;300 mg are being explored further. 21 pts had ALK+ history (18 NSCLC, 3 other). Among 18 evaluable ALK+ pts, 10 responded. 15 ALK+ pts had 0 (n=3) or 1 (n=12) prior ALK TKI (crizotinib); of these, 2/3 and 8/12 pts (67%) responded, including 2 complete responses. The longest response is 40 wks (ongoing). 4 of 5 ALK+ pts with untreated or progressing CNS lesions at baseline and with follow-up scans had evidence of radiographic improvement in CNS, including 1 pt resistant to crizotinib and LDK378 (overall response = stable disease). 16 pts had EGFRm history (15 NSCLC, 1 SCLC); 14 pts had ≥1 prior EGFR TKI. Of 12 EGFRm pts with a follow-up scan, 1 pt (prior erlotinib) responded at 120 mg (duration 21 wks, ongoing), 6 pts had stable disease (2 ongoing, duration 7-31 wks). Conclusions: AP26113 has promising anti-tumor activity in ALK+ pts, with initial evidence of activity in EGFRm pts, and is generally well tolerated. Phase II will begin after the recommended phase II dose is determined, with 4 cohorts: crizotinib-naïve NSCLC; crizotinib-resistant NSCLC; EGFR TKI-resistant NSCLC; other tumors. NCT01449461. Clinical trial information: NCT01449461.
Glycosylphosphatidylinositol Anchored TFPI As Main Regulator of Factor X Activation On the Surface of Endothelial Cells.
Authors: Michael Dockal, Robert Pachlinger, Angelina Baldin-Stoyanova, Fabian Knofl, Nadja Ullrich, Jadranka Koehn, Hartmut J. Ehrlich, Friedrich Scheiflinger
Journal: Blood (2012)
CONSISTENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL LOWERING EFFICACY OF ALIROCUMAB IN HIGH AND VERY HIGH CARDIOVASCULAR RISK PATIENTS WITH LOW-DENSITY LIPOPROTEIN CHOLESTEROL &gt;100/70 MG/DL AT BASELINE
Authors: Jennifer Robinson, Francois Schiele, Ulrich Laufs, Maddalena Lettino, Velichka Valcheva, Sophie Guillonneau, Serban R. Iorga, Nadège Narcisse, Keith Fox
Journal: Journal of the American College of Cardiology (2017)
Suicide prevention strategy must include quicker support for patients after discharge, say MPs
Authors: Gareth Iacobucci
Journal: BMJ (2017)

Patients being discharged from inpatient specialist mental health care should get follow-up support within three days to reduce their risk of suicide, a group of MPs has urged.

In its final report of its inquiry into suicide prevention,1 the House of Commons Health Committee said it was “disappointing” that the government’s January 2017 updated national suicide prevention strategy did not take on the committee’s recommendation, made in 2016,2 to improve on the current standard that patients should get follow-up support within seven days of discharge.

Around a third of people who ended their lives by suicide were in the care of specialist mental health services, the committee said, and …
PROGNOSTIC SIGNIFICANCE OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION PROGRESSION IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE I-PRESERVE TRIAL
Authors: Cesare Russo, Chelsea Jin, Lin Tao, Kaushal Desai, Alice Goshorn, Mark Donovan, Agata Ptaszynska
Journal: Journal of the American College of Cardiology (2017)
Treatment of advanced recurrent NSCLC with daily oral vinorelbine: A phase I trial.
Authors: Amanda Tufman, Astrid Borgmeier, Sylvia Guetz, Joachim Von Pawel, Achim Rittmeyer, Rudolf M. Huber
Journal: Journal of Clinical Oncology (2013)

e19108 Background: Metronomic regimens, in which small, frequent doses of chemotherapy are administered, have been suggested to lower toxicities while maintaining, or even improving, efficacy. The high frequency of administration aims to expose the tumor continuously to the drug, thereby preventing the recovery of malignant cells between cycles. Previous studies have shown that the administration of oral vinorelbine thrice weekly is feasible and well tolerated. We present a phase I dose finding study in which a regimen of daily oral vinorelbine was evaluated in pretreated patients with advanced NSCLC. Methods: Pretreated patients with advanced NSCLC were treated with vinorelbine (Navelbine oral) at fixed daily doses of 20 mg, 30 mg, 40 mg or 50 mg for 21 days of each four-week cycle. The primary end point was the identification of the maximum tolerated dose, which was reached when two out of six patients experienced dose limiting toxicity (DLT) in cycle 1 or 2. Results: 27 patients with advanced NSCLC (78% stage IV, median age 65 y) were enrolled. Most (93%) had received previous systemic therapy (mean: 2.6 lines). Daily administration of oral vinorelbine was well tolerated up to 30 mg/d without any DLT. At 40 mg one of three patients experienced DLT in cycle 1 and another patient in cycle 2. Three out of six patients had DLT at the dose level of 50 mg. Therefore, the recommended dose was established at 30 mg/d in cycle 1, with escalation to 40 mg/d in cycle 2 if no DLT had occurred. Eleven patients (2 out of 7 treated with the recommended dose) experienced treatment-related toxicities of grade 3 or higher. The adverse events were primarily hematological (febrile neutropenia: 14.8%, leukopenia: 29.6%, lymphopenia: 18.5%, neutropenia: 18.5%). One patient died as a result of colitis. The frequency of non-hematological toxicities of grade 3 or higher was low with only single cases reported for nausea, fatigue, neutropenic sepsis, pneumonia, increased gamma-glutamyltransferase and anorexia. Conclusions: Daily administration of oral vinorelbine in pretreated patients is feasible and safe. An initial dose of 30mg/d is well tolerated and can be increased to 40mg/d in cycle 2. Further studies are warranted to evaluate the efficacy and safety of this novel approach. Clinical trial information: EudraCT number 2006-001573-25.
THE IMPACT OF THE CURRENT VERSUS PRIOR CARDIAC RESYNCHRONIZATION GUIDELINES ON THE PROPORTION OF HOSPITALIZED HEART FAILURE PATIENTS ELIGIBLE FOR THERAPY
Authors: Kristin J. Lyons, Justin Ezekowitz, Li Liang, Paul Heidenreich, Clyde Yancy, Adam DeVore, Adrian F. Hernandez, Gregg Fonarow
Journal: Journal of the American College of Cardiology (2017)
HIGHER B-TYPE NATRIURETIC PEPTIDE LEVELS PREDICT OCCURRENCE OF ACUTE KIDNEY INJURY AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Stephan Haussig, Felix Woitek, Norman Mangner, Sergey Leontyev, David Holzhey, Friedrich Mohr, Gerhard Schuler, Axel Linke
Journal: Journal of the American College of Cardiology (2017)
MEAN PULMONARY ARTERY VELOCITY ESTIMATED BY CARDIAC MAGNETIC RESONANCE AS AN EARLY PROGNOSTIC INDICATOR IN HEART FAILURE WITH REDUCED EJECTION FRACTION IRRESPECTIVE OF RIGHT VENTRICULAR FUNCTION
Authors: Blanca Trejo Velasco, Oscar Fabregat-Andrés, María Pilar García-González, Mónica Ferrando, Diana Perdomo-Londoño, Cristina Albiach-Montañana, Rafael dela Espriella-Juan, Sergio Sánchez-Álvarez, Juan Pablo Cárdenas-Tealdo, Salvador Morell-Cabedo, Francisco Ridocci-Soriano
Journal: Journal of the American College of Cardiology (2017)
CA184-043: A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following a single dose of radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D).
Authors: Charles G. Drake, Howard I. Scher, Alberto Bossi, Alfons JM van den Eertwegh, Brent McHenry, Thomas F. Fitzmaurice, Jean-Marie Cuillerot, Kevin M. Chin, Paul Gagnier, Karim Fizazi, Winald R. Gerritsen
Journal: Journal of Clinical Oncology (2012)

TPS4689 Background: Ipilimumab (Ipi), a fully human monoclonal antibody which blocks CTLA-4, augments antitumor immune responses. Ipi has shown antitumor effects in prostate cancer model systems and clinical activity (via prostate-specific antigen [PSA] declines and RECIST response) in Phase 1/2 investigations in CRPC, with a side effect profile reflective of its mechanism of action. Preclinical data suggest that RT given prior to CTLA-4 blockade may increase antitumor activity. Methods: In this study, pts with CRPC who have progressed during or after D are randomized 1:1 to receive either a single dose of bone-directed RT followed by Ipi 10mg/kg, or RT followed by placebo. Within 2 days of RT administration (up to 5 lesions at 8 Gy on a single day) patients receive their initial dose of Ipi/placebo; Ipi/placebo is then given every 3 weeks for a total of 4 doses. Eligible pts may continue to receive blinded study drug every 12 weeks until they meet treatment stopping criteria, withdraw consent, are lost to follow-up, or study closure. The primary endpoint is overall survival (OS). Secondary endpoints include progression-free survival, pain response, and safety. The study is designed to detect a 3.8 month difference (HR=0.76) in median OS with 90% power and 0.05 2-sided type one error. The enrollment goal is 800 randomized patients, with a single interim analysis for superiority of OS planned at 435 events at approximately 33 months from first patient first visit (ClinicalTrials.gov identifier: NCT00861614). [Table: see text] [Table: see text]
ECHOCARDIOGRAPHIC ASSESSMENT OF RIGHT VENTRICULAR FUNCTION IN ACUTE RIGHT VENTRICULAR FAILURE IDENTIFIED BY HEMODYNAMIC CRITERIA
Authors: Veraprapas Kittipibul, Pakpoom Tantrachoti, Sanitpong Fongjunsom, Nath Zungsontiporn, Aekarach Ariyachaipanich, Sarawut Siwamogatham, Sarinya Puwanant
Journal: Journal of the American College of Cardiology (2017)
GRK2 Regulates α2-Adrenergic Receptor–Dependent Catecholamine Release in Human Adrenal Chromaffin Cells
Authors: Alessandro Cannavo, Daniela Liccardo, Anastasios Lymperopoulos, Michele Santangelo, Grazia D. Femminella, Dario Leosco, Antonio Cittadini, Nicola Ferrara, Nazareno Paolocci, Walter J. Koch, Giuseppe Rengo
Journal: Journal of the American College of Cardiology (2017)
Erratum: High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression
Authors: F Maura, A Guidetti, A Pellegrinelli, A Dodero, M Pennisi, C Caprioli, A Testi, L Farina, N Bolli, L F Devizzi, A Cabras, P Corradini
Journal: Blood Cancer Journal (2017)

Correction to: Blood Cancer Journal (2016) 6, e491; doi:10.1038/bcj.2016.99; published online 4 November 2016 Following the online publication of this article, it was noticed that the author names and affiliations were missing from the HTML version of this article. The complete names and affiliations are as follows:
A phase III randomized prospective trial of the effect of psychotherapy on distress in 287 prostate cancer patients: A URCC CCOP Study
Authors: O. Palesh, K. Mustian, C. Heckler, J. Purnell, L. Peppone, M. Weiss, J. N. Atkins, S. R. Dakhil, D. Spiegel, G. Morrow
Journal: Journal of Clinical Oncology (2009)

9637 Background: Cancer patients suffer from significant psychological distress, including mood and anxiety disorders. Psychiatric disorders are common in cancer and affect 22 to 43% of cancer patients. We previously showed that Supportive Expressive Group Therapy (SET) was effective in reducing distress in women with metastatic breast cancer. The current study expands our earlier research and examines the effect of SET on mood disturbance in prostate cancer patients. Methods: A sample of 318 cancer patients diagnosed with prostate cancer was assessed for mood disturbances by 9 geographically distinct URCC CCOP affiliates. The patients were randomly assigned to receive either 12 weeks of SET or education materials as a control. Patient-reported mood disturbance was assessed using the Profile of Mood States (POMS), a psychometrically valid and reliable measure of mood states, at baseline, 3, 6, 12, 18 and 24 months. Differences between treatment and control groups at follow-up were tested using a mixed-ANOVA model. The dependent variable was individual slopes on the POMS. Results: 287 patients (142 SET and 145 controls) provided complete data. No significant overall effect of intervention on mood was found (p=0.49) and the interaction between baseline mood scores and treatment arm was non-significant (p=0.075). There was a significant main effect for baseline mood (p&lt;0.0001) suggesting that those who have the greatest mood disruption at baseline improve with time independently of treatment arm. Conclusions: This is the first large randomized clinical trial using group psychotherapy among men with prostate cancer. Results suggest that a brief SET intervention does not improve distress among men with prostate cancer. Future studies might consider recruiting patients with particular psychosymptomatology and tailoring interventions. Supported by U10 CA37420 and NCI 1R25CA102618. No significant financial relationships to disclose.
LEFT VENTRICULAR DILATION: PATENT DUCTUS ARTERIOSUS VERSUS CHRONIC SEVERE MITRAL REGURGITAITON
Authors: Hiten R. Patel, Upamanyu Rampal, Kunal Patel, Fayez Shamoon, Irvin Goldfarb, Mahesh Bikkina
Journal: Journal of the American College of Cardiology (2017)
Reduced-Intensity Cord Blood Transplantation without Preceding Remission Induction Therapy Induces Durable Remission in Patients with Relapsed Acute Leukemia After the First Allogeneic Stem Cell Transplantation.
Authors: Toshimitsu Ueki, Kentaro Nasu, Ikuo Shimizu, Masahiko Sumi, Mayumi Ueno, Naoaki Ichikawa, Hikaru Kobayashi
Journal: Blood (2009)
REST SCAN DOES NOT IMPROVE AUTOMATIC MACHINE LEARNING PREDICTION OF MAJOR ADVERSE CORONARY EVENTS AFTER HIGH SPEED MYOCARDIAL PERFUSION IMAGING
Authors: Julian Andres Betancur, Yuka Otaki, Matthews Fish, Mark Lemley, Damini Dey, Balaji Tamarappoo, Guido Germano, Daniel Berman, Piotr Slomka
Journal: Journal of the American College of Cardiology (2017)
MATRIX METALLOPROTEINASE 9 DRIVES THE SHEDDING OF CD31 IN ACUTE CORONARY SYNDROMES
Authors: Giovanna Liuzzo, Davide Flego, Giulia Angelini, Ramona Vinci, Daniela Pedicino, Giuseppe Piemontese, Francesco Trotta, Anna Severino, Ada F. Giglio, Luigi Biasucci, Filippo Crea
Journal: Journal of the American College of Cardiology (2017)
Developmental Venous Anomalies Mimicking Neoplasm on 11C-Methionine PET and DSC Perfusion MRI
Authors: Julie H. Harreld, Mikhail Doubrovin, Elizabeth R. Butch, Angela Edwards, Barry Shulkin
Journal: Clinical Nuclear Medicine (2017)

Elevated relative cerebral blood volume on perfusion MRI and increased uptake on C-methionine PET can be used to diagnose and guide biopsy of brain tumors but are not specific. We report increased uptake on C-methionine PET associated with 4 developmental venous anomalies (DVAs) in 3 children with brain tumors, which could potentially mimic tumor and misdirect biopsy. Because DVAs are not readily visible on CT, prevention of misdirected biopsy in patients with focally elevated C-methionine uptake and relative cerebral blood volume relies on close correlation with contrast-enhanced anatomic MRI to exclude DVA or other nonneoplastic etiology.
TRENDS IN STATIN USE AMONG ADULTS IN AN INTEGRATED HEALTH CARE DELIVERY SYSTEM: IMPACT OF THE 2013 GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL
Authors: Kristi Reynolds, T. Craig Cheetham, Shen-Chih Chang, Jin-Wen Y. Hsu, Rong Wei, Deborah S. Ling-Grant, Teresa Harrison, Susan H. Boklage, Victoria Romo-LeTourneau, Ronald Scott
Journal: Journal of the American College of Cardiology (2017)
TIME OF PRESENTATION AMONG PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE (CLINICAL CHARACTERISTICS, INITIAL THERAPIES AND OUTCOMES): INSIGHTS FROM ASCEND-HF
Authors: Lukasz Cerbin, Andrew Ambrosy, Paul Armstrong, Javed Butler, Adrian Coles, Justin Ezekowitz, Stephen Greene, Adrian Hernandez, Marco Metra, Christopher O'Connor, Randall Starling, Wai Hong Tang, John Teerlink, Adriaan Voors, Angie Wu, Robert Mentz
Journal: Journal of the American College of Cardiology (2017)
Minimal residual local disease predicts improved survival after chemoradiotherapy in patients with squamous cell carcinoma of the esophagus
Authors: N. P. Rizk, L. Tang, B. J. Park, R. Flores, E. Venkatraman, M. S. Bains, D. Ilson, B. Minsky, V. W. Rusch
Journal: Journal of Clinical Oncology (2007)

15070 Background: Our recent analyses (JCO, in press) showed that residual nodal disease but not T-stage predicted survival after chemo-radiotherapy (CRT) and surgery for esophageal adenocarcinoma (AC). In this study, we investigated prognostic factors for esophageal squamous cell carcinoma (SCC) after CRT. Methods: Retrospective review of patients with esophageal SCC who had CRT and esophagectomy. Data collected: demographics, CRT details, pathologic findings, and survival. Statistical methods included recursive partitioning (RP) and Kaplan-Meier (KM) analyses. Results: Patients included in the study were treated between 1/1996 and 2/2006. Follow up was thru 5/06. 91 patients were appropriate for analysis. There were 56 men (61.5%) and 35 women (38.5%). 72 (79.1%) patients had clinical regional disease prior to treatment, while the rest had locally advanced disease. Median radiation dose was 5040 cGy, and 78 (85.7%) patients received cisplatin based chemotherapy. 49 (53.8%) patients had a complete local pathologic response (pCR), including 10/91 (10.9%) who had a pCR with residual nodal disease. 42 (46.2%) patients had residual local disease. RP analysis identified 3 prognostic groups: a) Group 1 (n=52), patients with minimal residual local disease (pCR &amp; T 1 - regardless of nodal status), b) Group 2 (n=28), patients with residual T 2 disease (N 0 and N 1 ) as well as patients with T 3–4 N 0 disease, and c) Group 3 (n=11), patients with residual T 3–4 N 1 disease. 3-year survival by KM analysis was 68.4% in group 1, 45.6% in group 2, and 0 % in group 3 (p&lt;0.001). Conclusions: Unlike adenocarcinoma of the esophagus where residual nodal disease after CRT is the most significant predictor of survival, in SCC of the esophagus, the presence of minimal residual local disease after CRT, regardless of nodal status, predicts the best survival. The implications of these findings might include establishing different endpoints to assess response to treatment and prognostic criteria. No significant financial relationships to disclose.
IN-HOSPITAL OUTCOMES AND HOSPITALIZATIONS FOR ACUTE RHEUMATIC HEART DISEASE: A UNITED STATES NATIONAL STUDY
Authors: Srikanth Yandrapalli, Sohaib Tariq, Venkat Lakshmi Kishan Vuddanda, Abdallah Sanaani, Zeeshan Solangi, Viswajit Reddy Anugu, Pratik Mondal, Merita Shehu, Sachin Sule, Wilbert Aronow
Journal: Journal of the American College of Cardiology (2017)